Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.53 |
| ▸ | NOS1 | P29475 | 5/20 | 0.53 |
| ▸ | NOS3 | P29474 | 4/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 4/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13615803 | 0.89 | IDH1 (0.49) | NOS2NOS1NOS3CPB2IDH1 | |
| SCHEMBL25704810 | 0.85 | CPB2 (0.40) | NOS2NOS1NOS3CPB2IDH1 | |
| SCHEMBL3625374 | 0.84 | GABRA1 (0.44) | NOS2NOS1NOS3TLR7GABRA1 | |
| SCHEMBL13040616 | 0.84 | NOS2 (0.58) | NOS2NOS1NOS3CPB2IDH1 | |
| SCHEMBL23153083 | 0.82 | MCHR1 (0.44) | NOS2NOS1NOS3CPB2IDH1 | |
| SCHEMBL11391327 | 0.80 | NOS2 (0.56) | NOS2NOS1NOS3IDH1BACE1 | |
| SCHEMBL15651026 | 0.80 | CPB2 (0.39) | NOS2NOS1NOS3CPB2IDH1 | |
| SCHEMBL12641681 | 0.77 | KCNH2 (0.41) | NOS2NOS1NOS3TLR7GABRA1 | |
| SCHEMBL2614966 | 0.77 | KDM4E (0.46) | NOS2NOS1NOS3GABRA1GABRB2 | |
| SCHEMBL7914665 | 0.76 | MCHR1 (0.39) | NOS2NOS1NOS3CPB2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054972-A2 | RADIONUCLIDE COMPOSITION AND METHOD OF USING SAME FOR DETECTION OF TUMOR CELLS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-113614087-B | WEE1 inhibitor and preparation and application thereof | 首药控股(北京)股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220194960-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (beijing) Co., Ltd. (CN) | 2022-06-23 | — | — | US | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| US-20210346353-A1 | CD73 INHIBITORS | ARCUS BIOSCIENCES, INC. | 2021-11-11 | — | — | US | disclosed |
| CN-113614087-A | WEE1 inhibitor, and preparation and application thereof | 首药控股(北京)股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| US-10960088-B2 | Macrocycles, cobalt and iron complexes of same, and methods of making and using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7312201-B2 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | NOS2 1291/4885NOS1 1244/4885NOS3 1409/4885 |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | NOS2 1681/4885NOS1 2517/4885NOS3 1721/4885 |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | NOS2 1543/4885NOS1 2008/4885NOS3 2072/4885 |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ABCB11, ABCB1, CYP2B6 | NOS2 1544/4885NOS1 2014/4885NOS3 735/4885 |
| US-20220194960-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | WEE1, WEE2, RCE1 | NOS2 3475/4885NOS1 2595/4885NOS3 3669/4885 |
| US-10960088-B2 | Macrocycles, cobalt and iron complexes of same, and methods of making and using same | ABCB7, FECH, CYC1 | NOS2 164/4885NOS1 243/4885NOS3 221/4885 |
| US-20210346353-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, NT5E | NOS2 1536/4885NOS1 1039/4885NOS3 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.